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Isoniazid preventive therapy (IPT) prevents tuberculosis (TB) in immunocompetent children <5 years of age after exposure to an infectious 
TB source case. Routine IPT has been advocated in all HIV-infected children without TB, but has been controversial. Antiretroviral therapy 
markedly reduces the risk for TB in HIV-infected children, especially when started early in infancy. In HIV-infected children, as in HIV-
uninfected children, we recommend post-exposure IPT after each TB exposure episode; but in HIV-infected children, this should be given 
irrespective of age or antiretroviral therapy. However, evidence for routine IPT without known exposure to TB in HIV-infected children is 
not convincing and is therefore not recommended.
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Isoniazid preventive therapy (IPT) effectively 
prevents tuberculosis (TB) in immunocompetent 
children <5 years of age, but its use in HIV-infected 
children remains controversial despite many studies 
and guidelines.
Recent World Health Organization (WHO) guidelines for IPT in 
HIV-infected children exclude infants (<12 months of age) from pre-
exposure IPT (i.e. IPT before known exposure to TB), based mainly 
on a large randomised double-blinded study that found no benefit 
in the first years of life.[1,2] IPT is recommended for older children, 
based on another randomised double-blinded study and supported 
by a cohort study of the same and additional children over a longer 
time period.[1,3,4]
However, it is known from the pre-treatment era and from a study 
in the HIV era in a high TB incidence area that infants infected with 
Mycobacterium tuberculosis in the first year of life are at greatest risk 
of developing TB.[5,6] If infants <12 months of age showed no benefit 
from pre-exposure IPT, it would seem unlikely that older children 
would benefit, although unrecognised exposure from outside the 
household is more likely in older children than in infants.[7]
The cohort study by Frigati et al.[4] showed that the most benefit 
for preventing TB was from starting antiretroviral therapy (ART), 
which reduced the risk for TB by 32%. Other studies in children 
and adults support ART significantly reducing the risk of TB disease 
after infection.[8-10] The cohort study,[4] a continuation of the study by 
Zar et al.,[3] also suggested a trend towards the benefit of adding IPT, 
unlike the study by Madhi et al.[2] In both studies, children exposed 
to TB were switched to open-label IPT.[2-4] Children receiving 
open-label IPT in the Madhi study were discontinued. In the study 
by Zar et al., while still in the double-blinded phase (isoniazid v. 
placebo), there was additional benefit in adding IPT as children were 
re-assigned to isoniazid v. placebo after receiving open-label IPT.[2,4] 
Other differences between the studies included severity of disease, 
availability of ART at baseline, ability to closely monitor adherence 
and size of the studies, which may account for confusion around the 
IPT policy for South Africa.
Most HIV-infected infants and children in South Africa should 
access ART as early as 8 - 10 weeks after birth, which should 
protect them to a large extent from developing TB as they would be 
immunologically similar to children without HIV infection. Hence, 
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the possible benefits of IPT need to be weighed against possible risks, 
especially when considering pre-exposure IPT.
Le Roux et al.[11] showed long-term IPT together with ART to be 
relatively safe in HIV-infected children; only 3.4% of children on ART 
and IPT developed grade 3 and 4 transaminase response, although 
none developed jaundice. However, the risk of hepatotoxicity and of 
developing isoniazid resistance if undiagnosed TB disease is treated 
with isoniazid alone is real.
Advice from various international and South African guidelines 
has caused uncertainty as to whether IPT should be given to all 
children without TB disease at initiation of ART.[1,12-14] Consequently, 
there is much uncertainty  among healthcare workers (HCWs) in 
terms of IPT implementation. Therefore, the Paediatric Essential 
Medicines List Committee supported by the National Department 
of Health’s HIV/AIDS, TB and Maternal, Child and Women’s Health 
(HIV/AIDS, TB & MCWH) branch provide (on weighing current 
evidence and the risks/benefits) the following  national guideline for 
IPT in HIV-infected and HIV-uninfected children:
1. In HIV-infected children, ART should start as early as possible in
infancy. Early ART has an important protective effect against the
development of TB following infection with M. tuberculosis.
2. Post-exposure IPT 10 mg/kg daily for 6 months is recommended
in the following children after exclusion of TB disease:
• HIV-uninfected children less than 5 years of age
• HIV-infected children irrespective of age or ART status.
Post-exposure means close contact with an infectious pulmonary 
TB case (defined as a sputum microscopy smear-positive or 
culture-positive or Genexpert-positive case) or the child is 
Mantoux tuberculin skin test-positive (induration ≥10 mm or, 
if HIV-infected, ≥5 mm) in the absence of previous IPT or TB 
treatment.
IPT should be repeated with each significant new exposure 
(isoniazid has no post-antibiotic effect, therefore no long-term 
protective effect after completing IPT).
In this regard, all HCWs should enquire about any new TB contact 
(new close TB source cases) at every follow-up visit, as well as 
asking caregivers about their own health, to screen for possible TB 
symptoms.
3. Pre-exposure IPT is not recommended in any HIV-infected or
-uninfected child.
4. Post-TB disease IPT is not recommended. Ensure when treating
TB in children that cure is complete. If resolution of TB is
incomplete, exclude drug-resistant TB disease (culture and drug
susceptibility testing supported by Genexpert tests) and, if no
drug-resistant TB is found, consider prolonging the continuation
phase to 7 months as provided for in the Essential Drug List in case 
of extensive disease or slow response to TB treatment. Repeated
exposure to TB is managed with exclusion of TB disease and IPT
as indicated as per point 2 above.
5. Post-exposure preventive therapy in children (HIV-uninfected or
HIV-infected) who are exposed to drug-resistant infectious TB
cases:
5.1.  True rifampicin (RIF) monoresistant contacts (confirmed
by culture-based drug susceptibility test results and not 
Genexpert RIF resistance): INH 10 mg/kg daily for 6 months 
should be provided.
5.2.  INH monoresistant contacts: RIF 10 - 15 mg/kg for 4 months 
as single drug (or in RIF/isoniazid if single drug RIF not 
available at the same RIF dose).
5.3.  Multidrug-resistant and extensive drug-resistant TB contacts: 
Evidence for preventive therapy is less clear and expert 
advice should be sought. Two recent publications address this 
situation.[15,16]
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